
Capricor Therapeutics (CAPR) Stock Forecast & Price Target
Capricor Therapeutics (CAPR) Analyst Ratings
Bulls say
Capricor Therapeutics Inc. demonstrates a positive outlook driven by the promising results of deramiocel, which has shown long-term safety and therapeutic durability without new safety signals, solidifying its favorable risk-benefit profile. The company is positioned for accelerated commercialization in Europe and the U.S. due to strategic partnerships that enhance pre-commercial activities and support manufacturing scale-up. Additionally, by focusing on DMD-cardiomyopathy, Capricor is effectively de-risking its Biologics License Application (BLA) submission plans, indicating potential for a faster path to market.
Bears say
Capricor Therapeutics Inc. faces a negative outlook primarily due to the inconclusive results of its clinical trials, specifically regarding deramiocel, which demonstrated only a modest reduction in disease progression over three years, with patients showing an average decline in the Performance of the Upper Limb 2.0 score. Additionally, the decline in the external comparator group raises concerns about the effectiveness of the treatment, as indicated by a statistically significant 7.19-point drop. Financially, the company's ability to advance its drug development is further threatened by potential difficulties in securing adequate funding, which could severely limit its operational progress and market presence.
This aggregate rating is based on analysts' research of Capricor Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Capricor Therapeutics (CAPR) Analyst Forecast & Price Prediction
Start investing in Capricor Therapeutics (CAPR)
Order type
Buy in
Order amount
Est. shares
0 shares